BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY

被引：0
|
作者：
Wu, C. Y. [1 ]
Wang, Q. [1 ]
Shi, J. [2 ]
Zhang, X. [3 ]
Du, R. [4 ]
Gu, J. [5 ]
Liu, Q. H. [6 ]
Yu, J. [1 ,7 ]
Xu, J. W. [1 ,7 ]
Zhang, Y. J. [1 ,7 ]
Zhu, H. [1 ]
Li, M.
Zeng, X.
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp PUMCH, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Yiyang Cent Hosp, Dept Rheumatol & Clin Immunol, Yiyang, Peoples R China
[3] Zibo Cent Hosp, Dept Rheumatol & Clin Immunol, Zibo, Peoples R China
[4] Huazhong Univ Sci & Technol, Wuhan Union Hosp, Tongji Med Coll, Dept Rheumatol & Clin Immunol, Wuhan, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Rheumatol & Clin Immunol, Guangzhou, Peoples R China
[6] Hubei Univ Med, Sinopharm Dongfeng Gen Hosp, Dept Rheumatol & Clin Immunol, Shiyan, Peoples R China
[7] Eli Lilly & Co, LCDDMAC, Shanghai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Real-world evidence; Safety; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.2148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0455 AB0
引用
收藏
页码：1418 / 1418
页数：1
相关论文
共 50 条
  • [21] A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
    Stradner, Martin H.
    Dejaco, Christian
    Brickmann, Kerstin
    Graninger, Winfried B.
    Brezinschek, Hans Peter
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [22] A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
    Martin H. Stradner
    Christian Dejaco
    Kerstin Brickmann
    Winfried B. Graninger
    Hans Peter Brezinschek
    Arthritis Research & Therapy, 18
  • [23] Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case postmarketing surveillance study
    Okamoto, Nami
    Atsumi, Tatsuya
    Takagi, Michiaki
    Takahashi, Nobunori
    Takeuchi, Tsutomu
    Tamura, Naoto
    Nakajima, Atsuo
    Nakajima, Ayako
    Fujii, Takao
    Matsuno, Hiroaki
    Ishii, Taeko
    Tsujimoto, Naoto
    Nishikawa, Atsushi
    Minatoya, Machiko
    Tanaka, Yoshiya
    Kuwana, Masataka
    MODERN RHEUMATOLOGY, 2024, 35 (02) : 215 - 224
  • [24] Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study
    Reich, K.
    Pinter, A.
    Lacour, J. P.
    Ferrandiz, C.
    Micali, G.
    French, L. E.
    Lomaga, M.
    Dutronc, Y.
    Henneges, C.
    Wilhelm, S.
    Hartz, S.
    Paul, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1014 - 1023
  • [25] Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study
    Nagy, Gyorgy
    Geher, Pal
    Tamasi, Laszlo
    Drescher, Edit
    Keszthelyi, Peter
    Pulai, Judit
    Czirjak, Laszlo
    Szekanecz, Zoltan
    Kiss, Gergely
    Kovacs, Laszlo
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 6 (02)
  • [26] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study
    Kameda, Hideto
    Nishida, Keiichiro
    Nanki, Toshihiro
    Watanabe, Akira
    Oshima, Yukiya
    Momohara, Shigeki
    MODERN RHEUMATOLOGY, 2024, : 1103 - 1114
  • [27] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
  • [28] Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
    Katlama, Christine
    Esposito, Roberto
    Gatell, Jose M.
    Goffard, Jean-Christophe
    Grinsztejn, Beatriz
    Pozniak, Anton
    Rockstroh, Jurgen
    Stoehr, Albrecht
    Vetter, Norbert
    Yeni, Patrick
    Parys, Wim
    Vangeneugdenk, Tony
    AIDS, 2007, 21 (04) : 395 - 402
  • [29] Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study
    Bi, L.
    Li, Y.
    He, L.
    Xu, H.
    Jiang, Z.
    Wang, Y.
    Li, X.
    Wei, W.
    Gu, J.
    Wang, G.
    Zhang, Z.
    Zhou, B.
    Liu, Y.
    Wu, Z.
    Liu, H.
    He, D.
    Lv, Z.
    Li, Z.
    Zuo, X.
    Dong, L.
    Wu, H.
    Zhang, H.
    Chen, H.
    Bao, C.
    Zhang, Z.
    Zhang, M.
    Song, H.
    Zheng, Y.
    Jiang, L.
    Liu, X.
    Boehnlein, M.
    Dunkel, J.
    Shao, J.
    Harris, K.
    Li, Z.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : 227 - 234
  • [30] Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study
    Yi-ting He
    Ai-hua Ou
    Xiao-bo Yang
    Wei Chen
    Li-yuan Fu
    Ai-ping Lu
    Xiao-ping Yan
    Xing-hua Feng
    Li Su
    Yue-jin Song
    Sheng-ping Zeng
    Wei Liu
    Xian Qian
    Wan-hua Zhu
    Ying-rong Lao
    Wei-hua Xu
    Ze-huai Wen
    Xiao-hong He
    Bao-juan Wang
    Geng-xin Chen
    Su-qin Xue
    Rheumatology International, 2014, 34 : 1647 - 1655
12345